Mishka Terplan1, Dennis J Hand2, Melissa Hutchinson1, Elizabeth Salisbury-Afshar1, Sarah H Heil3. 1. Behavioral Health System Baltimore, Baltimore, MD 21201, United States; Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD 21201, United States. 2. Vermont Center on Behavior and Health, University of Vermont, Burlington, VT 05401, United States; Department of Psychiatry, University of Vermont, Burlington, VT 05401, United States. 3. Vermont Center on Behavior and Health, University of Vermont, Burlington, VT 05401, United States; Department of Psychiatry, University of Vermont, Burlington, VT 05401, United States; Department of Psychology, University of Vermont, Burlington, VT 05401, United States.
Abstract
AIM: To systematically review the literature on contraceptive use by women with opioid and other substance use disorders in order to estimate overall contraceptive use and to examine method choice given the alarmingly high rate of unintended pregnancy in this population. METHOD: Pubmed (1948-2014) and PsycINFO (1806-2014) databases were searched for peer-reviewed journal articles using a systematic search strategy. Only articles published in English and reporting contraceptive use within samples of women with opioid and other substance use disorders were eligible for inclusion. RESULTS: Out of 580 abstracts reviewed, 105 articles were given a full-text review, and 24 studies met the inclusion criteria. The majority (51%) of women in these studies reported using opioids, with much smaller percentages reporting alcohol and cocaine use. Across studies, contraceptive prevalence ranged widely, from 6%-77%, with a median of 55%. Results from a small subset of studies (N=6) suggest that women with opioid and other substance use disorders used contraception less often than non-drug-using comparison populations (56% vs. 81%, respectively). Regarding method choice, condoms were the most prevalent method, accounting for a median of 62% of contraceptives used, while use of more effective methods, especially implants and intrauterine devices (IUDs), was far less prevalent 8%. CONCLUSIONS: Women with opioid and other substance use disorders have an unmet need for contraception, especially for the most effective methods. Offering contraception services in conjunction with substance use treatment and promoting use of more effective methods could help meet this need and reduce unintended pregnancy in this population.
AIM: To systematically review the literature on contraceptive use by women with opioid and other substance use disorders in order to estimate overall contraceptive use and to examine method choice given the alarmingly high rate of unintended pregnancy in this population. METHOD: Pubmed (1948-2014) and PsycINFO (1806-2014) databases were searched for peer-reviewed journal articles using a systematic search strategy. Only articles published in English and reporting contraceptive use within samples of women with opioid and other substance use disorders were eligible for inclusion. RESULTS: Out of 580 abstracts reviewed, 105 articles were given a full-text review, and 24 studies met the inclusion criteria. The majority (51%) of women in these studies reported using opioids, with much smaller percentages reporting alcohol and cocaine use. Across studies, contraceptive prevalence ranged widely, from 6%-77%, with a median of 55%. Results from a small subset of studies (N=6) suggest that women with opioid and other substance use disorders used contraception less often than non-drug-using comparison populations (56% vs. 81%, respectively). Regarding method choice, condoms were the most prevalent method, accounting for a median of 62% of contraceptives used, while use of more effective methods, especially implants and intrauterine devices (IUDs), was far less prevalent 8%. CONCLUSIONS:Women with opioid and other substance use disorders have an unmet need for contraception, especially for the most effective methods. Offering contraception services in conjunction with substance use treatment and promoting use of more effective methods could help meet this need and reduce unintended pregnancy in this population.
Authors: Sarah H Heil; Hendree E Jones; Amelia Arria; Karol Kaltenbach; Mara Coyle; Gabriele Fischer; Susan Stine; Peter Selby; Peter R Martin Journal: J Subst Abuse Treat Date: 2010-10-30
Authors: Don C Des Jarlais; Kamyar Arasteh; Theresa Perlis; Holly Hagan; Abu Abdul-Quader; Douglas D Heckathorn; Courtney McKnight; Heidi Bramson; Chris Nemeth; Lucia V Torian; Samuel R Friedman Journal: AIDS Date: 2007-01-11 Impact factor: 4.177
Authors: Stephen W Patrick; Robert E Schumacher; Brian D Benneyworth; Elizabeth E Krans; Jennifer M McAllister; Matthew M Davis Journal: JAMA Date: 2012-04-30 Impact factor: 56.272
Authors: Kaye Wellings; Kyle G Jones; Catherine H Mercer; Clare Tanton; Soazig Clifton; Jessica Datta; Andrew J Copas; Bob Erens; Lorna J Gibson; Wendy Macdowall; Pam Sonnenberg; Andrew Phelps; Anne M Johnson Journal: Lancet Date: 2013-11-26 Impact factor: 79.321
Authors: Brooke S West; Debbie M Cheng; Olga Toussova; Elena Blokhina; Natalia Gnatienko; Kan Liu; Jeffrey H Samet; Anita Raj Journal: AIDS Behav Date: 2018-06
Authors: Nicholas E Hagemeier; Ivy A Click; Heather Flippin; Holly Gilliam; Alexandra Ross; Jeri Ann Basden; Ronald Carico Journal: Int J Clin Pharm Date: 2017-12-05
Authors: Emily A Hurley; Alex Duello; Sarah Finocchario-Kessler; Kathy Goggin; Stephani Stancil; Rachel P Winograd; Melissa K Miller Journal: Am J Health Promot Date: 2020-05-29
Authors: Sarah H Heil; Dennis J Hand; Stacey C Sigmon; Gary J Badger; Marjorie C Meyer; Stephen T Higgins Journal: Prev Med Date: 2016-06-23 Impact factor: 4.018
Authors: Caitlin J Handy; Hannah L H Lange; Brittny E Manos; Elise D Berlan; Andrea E Bonny Journal: J Pediatr Adolesc Gynecol Date: 2017-11-21 Impact factor: 1.814